Table 4.
Ongoing clinical trials using dendritic cell vaccines in patients with high-grade glioma.
| Study | Phase | Estimated enrollment (n) | Status | Primary outcome(s) | Ref. |
|---|---|---|---|---|---|
| Phase II feasibility study of DC vaccination for newly diagnosed GBM | II | 11 | Ongoing | Tumor-specific, cytotoxic T-cell response | [202] |
| Vaccine therapy in treating patients with malignant glioma | I | 8 | Ongoing | Dose-limiting toxicity, survival, tumor progression and cellular immune response | [202] |
| Vaccine therapy in treating patients with newly diagnosed GBM | I | 16 | Ongoing | Safety and feasibilty | [202] |
| DC cancer vaccine for high-grade glioma (GBM-Vax) | II | 56 | Recruiting | PFS | [202] |
| Safe study of DC-based therapy targeting tumor stem cells in glioblastoma | I/II | 20 | Recruiting | Adverse events | [202] |
| Efficacy and safety of autologous DC vaccination in GBM after complete surgical resection | II | 37 | Recruiting | PFS | [202] |
| Vaccine therapy in treating patients with malignant glioma | I | 18 | Ongoing | Dose-limiting toxicity | [202] |
| DC vaccination for patients with solid tumors | I/II | 10 | Recruiting | Immunogenicity | [202] |
| Study of a drug [DCVax®-L] to treat newly diagnosed GBM brain cancer | III | 300 | Recruiting | PFS | [202] |
| A study of ICT-107 immunotherapy in GBM | II | 200 | Recruiting | OS | [202] |
| Vaccine therapy in treating patients undergoing surgery for recurrent GBM | I | 50 | Recruiting | Safety and feasibility | [202] |
DC: Dendritic cell; GBM: Glioblastoma multiforme; OS: Overall survival; PFS: Progression-free survival.